6185 — Cansino Biologics Balance Sheet
0.000.00%
Last trade - 00:00
- HK$4.08bn
- HK$2.56bn
- CNY345.18m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 755 | 5,114 | 7,783 | 5,947 | 4,120 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 23.1 | 136 | 631 | 1,106 | 697 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 794 | 5,421 | 9,290 | 7,730 | 5,181 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 608 | 917 | 2,317 | 3,179 | 3,134 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 1,784 | 6,748 | 11,874 | 11,469 | 9,319 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 124 | 413 | 2,875 | 2,942 | 2,592 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 314 | 677 | 3,879 | 4,721 | 4,044 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Other Equity | |||||
Total Equity | 1,471 | 6,071 | 7,995 | 6,748 | 5,275 |
Total Liabilities & Shareholders' Equity | 1,784 | 6,748 | 11,874 | 11,469 | 9,319 |
Total Common Shares Outstanding |